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Abstract
Background: Autism spectrum disorder (ASD), a developmental disorder of early childhood onset, affects males
four times more frequently than females, suggesting a role for the sex chromosomes. In this study, we describe a
family with ASD in which a predicted pathogenic nonsense mutation in the X-chromosome gene RAB39B
segregates with ASD phenotype.
Methods: Clinical phenotyping, microarray, and whole genome sequencing (WGS) were performed on the five
members of this family. Maternal and female sibling X inactivation ratio was calculated, and phase was investigated.
Mutant-induced pluripotent stem cells engineered for an exon 2 nonsense mutation were generated and
differentiated into cortical neurons for expression and pathway analyses.
Results: Two males with an inherited RAB39B mutation both presented with macrocephaly, intellectual disability
(ID), and ASD. Their female sibling with the same mutation presented with ID and a broad autism phenotype. In
contrast, their transmitting mother has no neurodevelopmental diagnosis. Our investigation of phase indicated
maternal preferential inactivation of the mutated allele, with no such bias observed in the female sibling. We offer
the explanation that this bias in X inactivation may explain the absence of a neurocognitive phenotype in the
mother. Our cellular knockout model of RAB39B revealed an impact on expression in differentiated neurons for
several genes implicated in brain development and function, supported by our pathway enrichment analysis.
Conclusions: Penetrance for ASD is high among males but more variable among females with RAB39B mutations.
A critical role for this gene in brain development and function is demonstrated.
Keywords: RAB39B, Intellectual disability (ID), RNAseq, Whole genome sequencing (WGS)
Background
Genomic microarray technology and genome sequencing
are changing our understanding of the genetic architec-
ture of autism spectrum disorder (ASD). This lifelong
neurodevelopmental disorder of early childhood onset
[1] is now known to be associated with rare inherited
and de novo genetic variation, comprising single nucleo-
tide variants (SNV), smaller and larger insertions and
deletions (indels and copy number variants, CNVs, re-
spectively), and other complex structural variation [2–4].
ASD affects males on average four times more fre-
quently than females, which strongly suggests an etio-
logical role for the sex chromosomes. However, the
majority of genes implicated in ASD, so far, are auto-
somal, with notable exceptions including MeCP2, the
NLGN genes, and FMR1. With an estimated 400 or
more genes involved in ASD’s etiology [5], there may re-
main several undiscovered ASD susceptibility genes on
the sex chromosome. For example, some X-linked genes
involved in intellectual disability (ID) may be contribu-
tory factors in ASD, particularly as more than 100 genes
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on the X chromosome have now been described in asso-
ciation with ID [6].
Our own whole genome sequencing (WGS) study
(www.mss.ng), currently comprising 2620 ASD genomes
from 2066 unique families, has identified a number of X
chromosome genes in which rare predicted damaging
mutations are enriched, including MECP2, NLGN3,
NLGN4, and PCDH11X [7]. One such gene, RAB39B,
has been described in the literature in association with
X-linked ID along with variable phenotypic manifesta-
tions including ASD, seizures, macrocephaly, delayed
psychomotor development, and early-onset Parkinson’s
disease or Parkinsonism [8–11]. This two-exon gene,
which comprises two protein domains, is a member of
the RAS oncogene family with known expression in neu-
rons and neuronal precursors, particularly in the hippo-
campus [8]. Along with other RAS proteins, it plays a
key role in intracellular vesicular trafficking. Specifically,
through its trafficking role, RAB39B is now known to
mediate the surface expression of GluA2, a subunit of
the glutamate AMPA receptor [12].
Here, we present a detailed description of a family in
which two brothers with ASD have a maternally inher-
ited loss of function (LoF) mutation in exon 2 of
RAB39B. Both males are now in their early 30s and have
ID with no functional language; they also have fine
motor difficulties and macrocephaly. Additionally, one
presents with a childhood onset unilateral hand tremor
and has marked slowing in the execution of simple, rou-
tinized movements. In addition, their female sibling,
who shares the RAB39B mutation, presents with mild ID
and a broad autism phenotype (BAP), but not ASD. Fi-
nally, the transmitting mother has a unilateral fine upper
intention tremor of unknown etiology. We examined the
impact of an exon 2 mutation on gene expression in dif-
ferentiated neurons using CRISPR/Cas.
Methods
The family described was recruited as part of ongoing
studies investigating the genetic etiology of ASD [7]. ASD
diagnoses are made by expert clinicians using the Autism
Diagnostic Interview (ADI) [13] and the Autism Diagnos-
tic Observation Schedule (ADOS) [14] combined with
clinical judgment. All data were collected following in-
formed consent from participants or substitute decision-
makers, and the study was conducted with approval from
the local research ethics board. The mother has provided
specific written consent for this case report.
Phenotypes
Both affected males were recruited into the study at the
same time, one aged 9 years (III-3, hereafter “proband”)
and the other 8 years (III-4) (Fig. 1). They had both been
diagnosed with ASD at age 3 years, and on recruitment
into the study, diagnostic clarification was sought with
ADI-R and ADOS-G. Additionally, nonverbal IQ was
measured using the Leiter-R, language using the Oral
and Written Language Scales (OWLS-II), and adaptive
function using the Vineland Adaptive Behavior Scales-II
(VABS). Their female sibling (III-5) was first assessed in
a specialist pediatric clinic because of developmental
concerns age 5 years. At the time of recruitment (age
6 years), she completed a measure of IQ (Wechsler
Intelligence Scale for Children) and her adaptive func-
tion was measured using the VABS. Assessment for ASD
was not completed during her childhood, but age
29 years the presence of autism traits of childhood onset
were ascertained by a maternally completed Social Re-
sponsiveness Scale (SRS) [15]. Head circumference was
also collected, and craniofacial features were evaluated.
Medical history was collected by way of a detailed ques-
tionnaire. The two males with ASD were re-evaluated
age 33 years (III-3) and 32 years (III-4). The Leiter-R
Fig. 1 Annotated pedigree of family described in the text
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and VABS were both repeated, and interim medical his-
tory was collected. Both parents completed the Toronto
Alexithymia Scale [16]. This scale measures alexithymia,
characterized by an inability to self-reflect on and label
emotions. Although neuropsychiatric and developmental
history was not specifically sought for either parent, both
are professionally employed and neither endorsed an
ASD diagnosis, or broader phenotype, during the collec-
tion of family history.
Genotypes
Members of the family were genotyped using either an
Affymetrix 500k (II-3, II-4, and III-3) [17] and/or Illu-
mina 1M (II-3, II-4, and III-4) [18, 19] microarray, and
CNVs were detected as previously published [18–20].
Briefly, multiple different CNV calling algorithms were
used to generate high-confidence CNV calls, with sup-
port from a minimum of two algorithms required, and
CNVs with a frequency of < 0.1% in controls (N = 9611)
prioritized as “rare.” CNVs with > 50% reciprocal overlap
were deemed identical. We also removed all CNVs that
had > 50% overlap with a known segmental duplication.
No CNVs of clinical significance, or of uncertain clinical
significance, were identified in this family. The proband,
his male and female siblings, and both parents also
underwent whole genome sequencing (WGS) by
Complete Genomics (Mountain View, CA) as previously
published [21]. Identified variants were annotated and
likely deleterious mutations prioritized to capture those
that were rare (MAF ≤ 1%), LoF (nonsense, splice site,
and frameshift), and damaging de novo missense muta-
tions (damaging as evidenced by SIFT ≤ 0.05, Poly-
phen2 ≥ 0.95, CADD ≥ 15, Mutation Assessor score ≥ 2
and PhyloP ≥ 2.4) [21]. For filtering, MAF was based on
the following control samples: 1000 Genomes Project,
NHLBI-ESP, ExAC, and Complete Genomics whole gen-
ome sequencing control data (CGI diversity panel and
Wellderly samples). Variants reported in this paper have
been validated by Sanger sequencing.
Extended family
Several members of the extended family (Fig. 1) were ge-
notyped for the RAB39B mutation. Although these indi-
viduals were unavailable for neuropsychiatric evaluation,
phenotypic data was collected through a family history
review provided by the mother (II-3).
X inactivation
The X inactivation (XI) ratio was calculated by charac-
terizing genotyped alleles according to the number of
CAG repeats on the highly polymorphic androgen re-
ceptor at Xq11-q12. The methylation-sensitive restric-
tion enzymes Hpa II and Hha I were used to cut the
repeat region on the active (but not inactive) strand
before and after quantitative PCR to determine the X in-
activation ratio. Non-methylated (active X) DNA seg-
ments digest with the enzymes and are thereby
unavailable for PCR amplification. Methylated (inactive
X) Hpa II/Hha I sites do not digest with enzyme and re-
main intact for amplification. Post-digestion PCR prod-
ucts therefore represent methylated (inactive X) DNA
sequences only. The androgen receptor was also geno-
typed on paternal and male offspring X-chromosomes to
facilitate phasing of the mutated allele. This thereby
allowed us to determine whether the mutated or non-
mutated allele was preferentially inactivated in mother
(II-3) and daughter (III-5).
Investigation of familial segregation
We estimated likely causality for the family’s RAB39B
mutation, and for all variants in RAB39B described in
the literature, using the method of Thompson et al. [22,
23]. This considers the segregation of the variant across
the full pedigree from which a Bayes factor (BF) is calcu-
lated. As articulated in the new ACMG-AMP guidelines
for variant classification [24], a BF of 8 or more provides
“supportive” evidence of pathogenicity, of 16 or more
“moderate” evidence of pathogenicity, and of 32 or more
“strong” evidence of pathogenicity.
iPS culture and differentiation
Skin fibroblasts from a healthy man were obtained at the
Hospital for Sick Children under the approval of the
SickKids Research Ethics Board, and induced pluripotent
stem cells (iPSCs) were generated and characterized as
previously published [25]. Cultured iPSCs were main-
tained on Matrigel® (Corning). One million iPSCs were
nucleofected using Nucleofector II (Amaxa) device with
program A-023 in Solution I with 5 μg Cas9D10A plasmid
(Addgene, #44720), 3 μg each of two gRNA cloning plas-
mids (Addgene, #41824) containing paired gRNAs A
(AAGAGGTTGTCAAATCAGAGAGG) and B (TCTGAA-
GAGTGAACCACATTTGG) targeting exon 2 of RAB39B,
and 1 μl of 100 μM single-stranded oligonucleotide
(ssODN) containing two 60 nucleotide-long arms of hom-
ology flanking a 3xSTOP, i.e., stop codons in all three read-
ing frames. This introduced mutation is not the same as
that involved in the family described. Cells were
evenly distributed in a 96-well plate. At confluency,
genomic DNA was extracted and droplet digital PCR
(ddPCR) was performed to determine the absolute
quantification of mutant alleles in each well. The mu-
tant stem cell clone was then differentiated into cor-
tical excitatory neurons. A comparison cell line was
generated from the isogenic control line, i.e., the
same line from which the knockout described above
was made.
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RNAseq
RNeasy® mini kit (Qiagen) was used to extract total RNA
from mature neurons. RNA samples were submitted to
an Agilent Bioanalyzer 2100 RNA Nano chip for quality
control. Concentration was determined using Qubit
RNA HS Assay on a Qubit fluorometer (ThermoFisher).
RNA libraries were prepared using NEBNext Ultra RNA
Library Preparation kit for Illumina. Briefly, 500 ng of
total RNA was used for poly-A mRNA enrichment be-
fore being split into 200–300 bp fragments for 4 min at
94 °C. Fragments were converted to double-stranded
cDNA, end-repaired, and adenylated in 3′ to create an
overhang A, allowing ligation of Illumina adapters with
an overhang T. Fragments were amplified and RNA li-
brary integrity was verified on a Bioanalyzer 2100 DNA
high-sensitivity chip (Agilent Technologies) and quanti-
fied using Kapa Library Quantification Illumina/ABI
Prism Kit protocol (KAPA Biosystems). Stranded librar-
ies were pooled in equimolar amounts and sequenced
on an Illumina HiSeq 2500 platform using a high-
throughput run mode flowcell and the V4 sequencing
chemistry to generate paired-end reads of 126-bases in
length, following Illumina’s recommended protocol. Data
quality was assessed using FastQC v.0.11.2. Trimmed
reads were screened for presence of rRNA and mtRNA
sequences using FastQ-Screen v.0.4.3. RSeQC package
v.2.3.7 was used to assess read distribution and pos-
itional read duplication and confirm strandedness of
alignments. Raw trimmed reads were aligned to the ref-
erence genome hg19 using Tophat v.2.0.11. Tophat
alignments were processed to extract raw read counts
for genes using htseq-count v.0.6.1p2. Raw gene counts
were loaded and sample-normalized using DESeq
v.1.18.0. Principal component analysis (PCA) was per-
formed to assess relation among samples. Two-
condition differential expression was done with the
edgeR R package, v.3.8.6 on four (RAB39B knockout)
and six (control) independent experiments. Cpm filter
was adjusted to the size of each library set to obtain at
least 8–10 reads in at least two samples. EdgeR results
were evaluated using FDR with a cutoff of 0.05.
Pathway enrichment
Pathway enrichment analysis was then performed using
the R package goseq version 1.24.0 and R version 3.3.1
(2016-06-21) using a custom gene set collection includ-
ing 6008 from gene ontology (GO, obtained from the R
package GO.db version 3.3.0) and 1723 from pathways
(KEGG, Reactome, NCI collections downloaded from
the respective websites on 20170120). GO terms were
obtained from the R package org.Hs.eg.db v3.4.0. Gene
sets were filtered by size to remove both very generic
and very specific terms. To aid in reproducibility, the
filtered gene set definitions are in Additional file 1:
human_GO_15_800_PATH_10_500.gmt.
Results
Phenotypes
The proband (III-3, Fig. 1) was evaluated age 3 years be-
cause of parental concerns regarding speech delay and
poor socialization and diagnosed with ASD. Parents re-
ported that his speech was developing well up until
18 months with the acquisition of a small number of
well-articulated words, but then plateaued. At 36 months,
he presented as a loner who had no interest in commu-
nicating or interacting with others, and he failed to use
eye-to-eye contact. Gross and fine motor milestones de-
veloped within normal limits, and there were no other
medical concerns. Morphological abnormalities included
a head circumference on the 98th percentile and finger
syndactyly. By 8 years, his language had improved, al-
though was comprised predominantly of echolalia. As-
sessment of intellectual ability and adaptive functioning
age 9 years were consistent with a diagnosis of ID, and
ADI-R [13] and ADOS [14] assessments completed at
this time were both consistent with a diagnosis of ASD
(Table 1 and Additional file 2: Table S1). He was further
assessed age 33 years. Interim medical history was nega-
tive for major medical or psychiatric illness, and re-
evaluation at this time revealed very little change in
symptoms. A number of movement-related symptoms
were noted, including impaired fine motor control and
episodic difficulties initiating movements. He was also
noted to have a fine bilateral tremor of his hands, worse
when agitated or anxious.
The proband’s male sibling (III-4) was evaluated age
3 years because of parental concerns with language delay
and diagnosed with ASD. At 36 months, he used no
functional language and was socially aloof. His motor
milestones were normal. He was on the 98th percentile
for head circumference and had epicanthic folds, a high-
arched palate, and a finger syndactyly. By 6 years, he had
developed some language skills, although failed to use
this to facilitate interaction with others. Assessment of
intellectual ability and adaptive functioning age 8 years
were consistent with a diagnosis of ID, and ADI-R and
ADOS at the time were both consistent with ASD
(Table 1). When re-evaluated age 32 years, he had some
limited language skills although his nonverbal IQ and
adaptive skills had changed little from childhood. An in-
terim medical history did not identify any major medical
or psychiatric illness. No movement-related symptoms
were identified, although he, too, had major difficulties
with fine motor control, impacting feeding, dressing,
and other instrumental activities of daily living.
Their younger female sibling (III-5) was first evaluated
when she was 5 years because of concerns with speech
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delay. She was described as responsive and curious as an
infant and became securely attached to her primary
caregivers. However, her speech developed late, and ar-
ticulation and intonation abnormalities were noted. She
was described as aloof from her peers and content to
play by herself. Assessment of intellectual ability and
adaptive functioning age 6 years were consistent with a
diagnosis of ID (Table 1). Morphologically, she was on
the 50th percentile for head circumference at the time of
assessment and had a left-sided epicanthus. Although
she was not assessed for ASD during childhood, a ma-
ternally completed SRS [15] when she was 29 years indi-
cated a moderate degree of impairment, consistent with
BAP. She was unavailable for further diagnostic testing.
Both parents completed a range of assessments that
indicated intellectual ability and language functioning in
the average range. Both parents’ scores on the Toronto
Alexithymia Scale [16] were consistent with alexithymia
(father = 70, mother = 60, scores 61 and above being
consistent with alexithymia). At the time of assessment,
parents were in full-time professional employment. Ma-
ternal self-report indicated a diagnosis of a persistent
left-sided intention tremor of unknown etiology, but no
other neurological history. Members of the extended
family were unavailable for phenotypic evaluation (Fig. 1).
However, review of the family history according to the
mother was negative for ASD, other developmental dis-
orders, neuropsychiatric diagnoses, or major medical ill-
ness in extended family members.
Genetics
A nonsense variant in exon 2 of RAB39B (Xq28,
g.154,490,171C>A, c.559G>T, [p.E187X], NM_171998,
CADD=12.46) was identified in both males with ASD,
inherited from their mother. The female sibling was
found to be heterozygous for this variant by WGS and
Sanger sequencing. The variant was absent from all
members of the extended family who were tested (Fig. 1).
Analysis of X inactivation in the mother and daughter
showed the mother had preferential inactivation of the
mutated allele (67%:33%, mutated allele: non-mutated al-
lele), whereas her daughter showed no such bias
(48%:52%, mutated allele: non-mutated alleles). RAB39B
is given a pLI score of 0.72 in the Exome Aggregation
Consortium (ExAC), consistent with intolerance to mu-
tation [26]. No individuals with this mutation are listed
Table 1 Genetic and clinical data from family segregating a RAB39B mutation
II-3 II-4 III-3 III-4 III-5
Age at first assessment
(months)
NA NA 36 36 60
Sex F M M M F
Microarraya NS NS NS NS NS
WGSb Xq28, RAB39B,
g.154,490,171C>A
3p26.3, CNTN6,
g.1,443,180G>A
WT
RAB39B
WT
CNTN6
Xq28, RAB39B,
g.154,490,171C>A
3p26.3, CNTN6,
g.1,443,180G>A
Xq28, RAB39B,
g.154,490,171C>A
3p26.3, CNTN6 g.1,443,180G>A
Xq28, RAB39B,
g.154,490,171C>A
WT CNTN6
Growth
Head circumference
(%ile)
NA NA 98th 98th 50th
Neurodevelopment
Full-scale IQ 110 109 39 32 69
Speech delay NA NA + + +
ASD − − + + +
Other
neurodevelopmental
NA NA − − −
Neurological
Epilepsy − − − − −
Parkinson − − − − −
Other neurological Tremor NA Tremor, bradykinesia, poor
fine motor
Poor fine motor −
Congenital NA NA Syndactyly Syndactyly, epicanthus, high-
arched palate
Left epicanthus
Other medical NA NA − − −
NA information not available, +/− positive/negative for attribute
aNS implies no variants of pathological significance, or variants of unknown significance contributing to ASD identified
bWT wild type
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in ExAC. A Bayes factor calculated from the pattern of
segregation of this mutation in the family is consistent
with moderate to strong evidence of pathogenicity ac-
cording to the ACMG-AMP guidelines (BF = 26.1) [24].
The two affected males also inherited from their
mother a nonsense variant in CNTN6 (3p26.3, g.1,443,
180G>A [p.W923X], NM_001289080, CADD=13.85), a
gene implicated in ASD. This variant is observed in one
non-Finnish European individual in ExAC, which assigns
this gene a pLI score of 0, suggesting greater tolerance
to mutation than RAB39B. The frequency of this muta-
tion in ExAC is 8.44e-06. This mutation was not shared
by their female sibling. However, one maternal sibling
reported to be normal from a neurodevelopmental
perspective also had this mutation (II-7). No clinically
significant CNVs were identified.
We investigated our own data for evidence of RAB39B
mutations in other individuals with ASD (N = 2620)
(www.mss.ng). One male was identified with a mater-
nally inherited 13 kb deletion (chrX:154,477,501-
154,490,661 [hg19]). He is described as exhibiting classic
symptoms of ASD with speech delay (age of single words
= 78 months). No further information is available. We
also investigated for the presence of CNVs and SNVs in
CNTN6. Among cases with ASD, five individuals have
exon impacting SNVs and 15 exon impacting CNVs (3
deletions and 12 duplications). No individuals were iden-
tified with variants impacting both CNTN6 and
RAB39B.
iPSC and expression studies
We used CRISPR/Cas to create a mutation in exon 2 of
RAB39B. Although the mutation generated in this way is
not identical to the family’s, it does provide insight into
the impact of an exon 2 loss of function mutation on
differential patterns of gene expression. A number of
genes were differentially expressed between mutant and
control lines (Fig. 2a, b; Additional file 3: RAB39B4_vs_-
Controls6_RPKM_Filt.txt). Figure 2 specifically high-
lights those differentially expressed genes that were
previously found associated with ASD and are present in
the Simons Foundation Autism Research Initiative
(SFARI) database. Among these top hits are known
SFARI syndromic genes (HCN1, C12orf57) and one high
confidence ASD-risk gene (GRIN2B). There are also two
genes, GABRA4 and GABRB2, that code for subunits of
the GABA receptor, the major inhibitory neurotransmis-
sion unit in the mammalian brain. Moreover, several
genes encode elements of the potassium channel
(KCNIP2, KCNK13, KCNIP2). Finally, NXPH1 encodes a
protein that forms complexes with alpha-neurexins, im-
plicating its role in cellular adhesion in the brain. We
next conducted gene set enrichment analysis to identify
the associated GO terms with the 260 differentially
expressed genes with FDR < 0.05 (Additional file 4:
enrichment_RAB39B4_vs_Controls6.txt). Only downreg-
ulated genes were significant, with their GO terms pro-
vided in the Additional file 5: Table S2. The enriched
terms point to the involvement of these downregulated
genes in neuron fate, neurogenesis, and regulation of
nervous system development.
We curated all of the descriptions of RAB39B patients
from the literature (Fig. 3). Five families have been de-
scribed, each with a unique variant [8, 9, 11], along with
one further individual identified from a sample of 1348
patients with Parkinson’s disease (PD) [10]. In one family
(Fig. 3, Reference 1), six males with ID and macroceph-
aly are described with a RAB39B splice donor variant
(hg19: 154,493,358, c.215+1G>A) [8]. Two males are also
diagnosed with ASD. In another family (Fig. 3, Reference
2), four males with ID, three of whom were also diag-
nosed with epilepsy, inherited a RAB39B nonsense mu-
tation in exon 1 (hg19: 154,493,553, c.21C>A [p.Tyr7X])
[8]. In two other families (Fig. 3, References 3 and 4),
macrocephaly, ID, and Parkinsonian symptoms are re-
ported [9]. In both families (7 males and 3 males re-
spectively), all males exhibit ID and, additionally,
Parkinsonian symptoms, ranging from childhood onset
tremor to akinetic-rigid PD of early onset and character-
ized by Lewy body brain pathology. The underlying mu-
tation in one family is a missense mutation (hg19:
g.154,490,227, c.503C>A [p.Thr168Lys]), bioinformati-
cally predicted to be damaging, while the other family
has a 45 kb deletion spanning the whole RAB39B gene
along with the distal 3 exons of the adjacent gene CLIC2,
also involved in X-linked ID. One other family comprises
seven males with Parkinsonian symptoms (Fig. 3, Refer-
ence 5), two of whom were diagnosed with ID. This fam-
ily has a missense variant (hg19: g.154,490,156,
c.574G>A [p.A192G]). One further male individual
(Fig. 3, Reference 6) identified in a clinical sample of
1348 individuals with PD had a nonsense mutation and
presented with ID and PD, but no further family history
is available. Five unique point mutations are described in
these patients, with two residing in the C-terminal chain
(one missense, one nonsense), both in families ascer-
tained for PD but with incomplete penetrance for ID.
CADD scores for all point mutations are consistent with
pathogenicity, and none are reported in ExAC (Add-
itional file 5). Moreover, calculations of co-segregation
for each family were consistent with strong evidence of
pathogenicity in 2, supporting evidence in 1 but only
marginal odds in favor of pathogenicity in the other
(Fig. 3).
Discussion
This paper illustrates the clinical features in a family seg-
regating a nonsense mutation in RAB39B. Consistent
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with previously described cases, both affected males had
ID with macrocephaly [8]. In addition to ID, both males
had language delay and fine motor deficits and were diag-
nosed with severe ASD. Despite the association with ASD
demonstrated by these two cases, examination of our
wider ASD datasets (microarray and WGS) found only
one further individual with a variant in RAB39B. We also
expand the phenotype to include musculoskeletal abnor-
mality, specifically syndactyly, which was observed in both
affected males. We had the opportunity to reassess the
brothers in their early 30s. Although the literature also de-
scribes early-onset PD among individuals with RAB39B
mutations [9–11], neither individual’s presentation was
consistent with PD, although one male presented with a
tremor and bradykinesia. It remains possible, of course,
that PD may develop later in these individuals. Addition-
ally, no change in severity of ASD symptomatology was
observed into adulthood, and both males remained
dependent on others for all aspects of care.
Our calculation of co-segregation was consistent
with moderate evidence of pathogenicity. Its absence
in ExAC and the calculated pLI score of 0.72 are
consistent with intolerance of this gene to mutation.
The other families described in the literature are also
characterized by strong co-segregation of the muta-
tion with phenotype, with odds (BF) in favor of caus-
ality varying from 6 to 165. Based on the evidence,
therefore, it seems reasonable to conclude at this
Fig. 2 Levels of transcript of selected genes in control and RAB39B-/γ-glutaminergic neurons as determined by RNAseq experiment. Values are
presented as mean ± SD of four (RAB39B) and six (control) independent experiments
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stage that rare damaging missense and LoF mutations
in RAB39B are highly penetrant for neurodevelop-
mental phenotypes among males.
Our study also examined the clinical characteristics in
the unaffected female sibling. This individual presented
with milder developmental vulnerabilities than her sib-
lings, although she clinically has ID and BAP. Also of
note, the transmitting mother in our family had devel-
oped a fine motor tremor of her left upper limb, diag-
nosed by her family physician as an intention tremor of
uncertain etiology. It is unclear whether this is related to
her RAB39B mutation. The DECIPHER [27] and ISCA
[28] databases contain descriptions of female carriers of
RAB39B CNVs who have developmental phenotypes in-
cluding ID, but none of those described has a movement
disorder. In general terms, the RAB39B families de-
scribed in the literature do not include phenotypic de-
scriptions for the carrier females: several allude to
normal phenotype and only one specifically describes a
female carrier with ID and tremor.
Our own data at least support the strong possibility
that some female carriers of RAB39B mutations are not
without clinical consequence, although the mechanism
is unclear. Phenotypic manifestation among female car-
riers of X-linked disorders has been previously reported,
and, with the notable exception of X-linked dominant
disorders such as Rett syndrome, are deemed to be due
to skewed patterns of XI [29]. Specifically, skewed inacti-
vation, which results in the normal allele being inacti-
vated significantly more frequently than the mutated
allele, may result in clinical consequence. Our own in-
vestigation of XI in this family identified preferential in-
activation of the mutated allele in the mother, with no
such bias in her daughter. This differential pattern of XI
may offer an explanation for the absence of neurocogni-
tive phenotype in the mother, but presence of broad aut-
ism phenotype in her daughter.
Both male offspring also harbored a CNTN6 loss of
function mutation, which was maternally inherited and
shared by a maternal aunt. This gene belongs to the
a
b
Fig. 3 Literature curation for RAB39B mutations
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contactin family of proteins, a group of brain-expressed
proteins that mediate cell surface interactions during
nervous system development and are key proteins in the
development of sensory-motor pathways. A recent study
has identified that, while not being fully penetrant, a sig-
nificant enrichment is observed among individuals with
ASD for deletions and private coding sequence variants in
CNTN6, with a phenotype that also includes hyperacusis
[30]. We are unable to examine the relative contribu-
tions of mutations in CNTN6 and RAB39B in this
family, and given the low frequency and variable loca-
tion of mutations in these genes, currently available
datasets are unlikely to offer much more in the way
of statistical power. Indeed, only five other individuals
were identified with SNVs impacting CNTN6 and 15
with CNVs, among whom only three were deletions.
In our own experience, this situation is not unusual
however, perhaps suggesting a modifying impact of
one of the genes on phenotype [31].
Recent research has begun to elaborate the function
of RAB39B. It is strongly brain-expressed, the
expressed protein principally located in the Golgi ap-
paratus of neurons. It has been shown to interact with
PICK1, with RAB39B-PICK1 interaction a necessary
step in RAB39B mediated trafficking of GluA2 [12],
thereby altering synapse activity. We extend these mo-
lecular findings through our own knockout of exon 2
of RAB39B using CRISPR/Cas in conjunction with
iPSCs. Differential expression analysis identified a
number of key brain-expressed genes. A number, such
as GRIN2B, GABRA4, GABRB2, and NXPH1, were up-
regulated, whereas others, including CACNG7 and
ETFB, were downregulated. Several of these have
already been earmarked for their crucial role in neuro-
development, supported by our GO enrichment ana-
lysis. In particular, the two enriched terms “regulation
of nervous system development” and “regulation of
neurogenesis” are consistent with RAB39B’s wider role
in multiple brain processes.
Conclusion
In summary, we have described a family segregating a
nonsense mutation of RAB39B occurring in association
with a variable phenotype including ID, ASD, and motor
symptoms. Our study extends the RAB39B literature in
the observation that female carriers are not without
clinical consequence, with the two female carriers of this
X-linked mutation in our family exhibiting milder clin-
ical features. Newly identified cases with mutations of
this gene will need to be followed through early adult-
hood and beyond to fully evaluate their motor function
and for evidence of neurodegenerative features and, in
this way, to fully grasp the spectrum of phenotype asso-
ciated with aberrations of this gene.
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